MEILLEUREHEALTH2327.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, MEILLEUREHEALTH (2327.HK) trades at a P/E of 13.80x, P/B of 0.54x, P/S of 3.85x, and a dividend yield of 3.16%.
Longitudinal percentile comparison: P/E sits at the 1st percentile over the trailing 10Y window (vs. 3rd percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 44th percentile within its industry and the 60th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 3.45%, ranking at the 68th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 2.5 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 3.45% total shareholder yield, 3.16% is paid out as dividends and roughly 0.29% is implied to come from buybacks — both channels are meaningfully in play. MEILLEUREHEALTH operates in the Other Pharmaceuticals and Medical Services sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2327 · SEHK: 2327 · 2327
Want the full picture on whether MEILLEUREHEALTH (2327.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 13.80 | ||||||
| P/B (MRQ) | 0.54 | ||||||
| P/S (TTM) | 3.85 | ||||||
| Dividend Yield | 3.16% | ||||||
| Buyback + Div Yield | 3.45% |